Federal Judge Trims Claims In Securities Class Action Over FDA Drug Approval

Mealey's (March 4, 2016, 1:42 PM EST) -- TRENTON, N.J. — A federal judge in New Jersey on March 2 granted in part and denied in part a motion to dismiss filed by defendants in a securities class action lawsuit, ruling that although lead plaintiffs have properly pleaded their federal securities law claims against a pharmaceutical company, they have failed to do so against a number of the company’s current and former officers and directors (Bing Li v. Aeterna Zentaris Inc., et al., No. 14-7081, D. N.J.; 2016 U.S. Dist. LEXIS 26772).

(Opinion available....
To view the full article, register now.